Close
Solutions
Online Inquiry

CONTACT US

USA:

UK:
Call us at:
USA:
UK:
Fax:
Email:

One-stop CAR-NKT Therapy Development

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The remarkable results of chimeric antigen receptors (CARs) clinical studies have improved the function and therapeutic efficacy of redirected T cells. However, several challenges have been encountered, and limit their anti-tumor potential and increase the risk of toxicity due to the high heterogeneity of CAR-T cells. Natural killer T cells (NKT) are immune cells, known for their powerful anti-cancer properties, and show potential for enabling autologous and allogeneic/off-the-shelf cancer immunotherapy.

At Creative Biolabs, we provide one-stop services for CAR-NKT therapy development, ranging from CAR construct design and optimization, CAR virus particle packaging, CAR carrying NKT cell engineering, to preclinical and clinical evaluation of CAR cells. We are dedicated to providing high-quality customized service to best meet your research needs, turnaround time, and budget requirements.

Advantages of CAR-NKT cells over conventional CAR-T cells

  • NKT cells have a spectrum of anti-tumor activities.
  • NKT cells would be able to directly kill tumor cells.
  • NKT cell activation indirectly activates two other types of immune cells, NK and T cells, to promotes an anti-tumor response.
  • Most importantly, in contrast to CAR T cells from the same donors, CAR NKTs did not induce multi-organ graft-versus-host disease.

The potential of iPSC-derived NK cells as a template for engineering. Fig.1 Functional advantages of CAR-NKT cells over conventional CAR-T cells. (Shissler, 2017)

iPS-NKT Cells Platform for CAR-NKT Therapy Development

Creative Biolabs has developed a state-of-art CAR-Stem Cell Platform for manufacturing iPSC-NKT cells. The workflow mainly consists of the following steps:

1) NKT reprogramming

NKT cells extracted from a healthy donor are reprogrammed to generate NKT-iPSC (NKT cell-derived iPSC), which exhibits unlimited expansion capacity.

2) NKT-iPSC differention

The NKT-iPSC is stimulated by cytokines to differentiate into iPSC-NKT (iPSC NKT-derived regenerated NKT) cells, resulting in a population of iPSC-derived CAR-NKT cells that can be used for multiple patients.

3) Tumor recognition and killing

The iPSC-derived CAR-NKT cells infused in the patient selectively recognize the tumor cells expressing the antigen and mediate the killing.

Workflow for our iPSC-derived NKT cell platform.Fig 2. Workflow for our iPSC-derived NKT cell platform.

One-Stop CAR-NKT Therapy Development

As the leading cell therapeutics biotech that provides cell therapy related services, Creative Biolabs provides one-stop services for CAR-NKT therapy development, including but not limited to:

If you are interested in our services, please send an email to contact us, and our team will get back to you as soon as possible.

Reference

  1. Shissler, S. C., et al. (2017). Mixed signals: co-stimulation in invariant natural killer T cell-mediated cancer immunotherapy. Frontiers in immunology, 8, 1447.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Online Inquiry

For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Key Updates

Receive our latest news and insights.